Black checkmark with a sparkle and a curved line underneath on a white background.
Company

VYNE Therapeutics Inc.

Ticker
VYNE
Sector
Industry
Report date
November 13, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent news coverage does not include material updates specific to VYNE Therapeutics. The company’s latest SEC filings provide the most current insights into its financial and operational status.

Recent developments:
  • VYNE Therapeutics reported a net loss of $26.5 million for the year ended December 31, 2025, with royalty revenues of $570,000 and operating expenses of $30.3 million, reflecting reduced R&D spending due to winding down clinical trials [S1].
  • As of September 30, 2026, the company held $268.9 million in cash and equivalents, with a current ratio of 42.08, indicating strong liquidity [S2].
  • The company operates fully remotely since November 1, 2025, with no operating lease obligations as of December 31, 2025 [S1].
  • Shares outstanding increased significantly from approximately 14.8 million at the end of 2024 to 33.3 million at the end of 2025, reflecting equity issuances [S1].
  • Risk factors disclosed in the latest 10-Q filing remain consistent with prior disclosures, with no material changes reported [S2].
Overview

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies, with recent wind down of clinical trials for repibresib and VYN202. The company generates limited royalty revenues and incurs significant operating losses primarily due to research and development and general administrative expenses. It has a strong cash position and liquidity ratios as of Q3 2026, supported by proceeds from marketable securities. The company transitioned to a fully remote operating model in late 2025 and has no significant lease obligations. Equity issuances have increased shares outstanding substantially over recent years.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company with detailed SEC filings through 2025 and Q3 2026. The company reported a net loss of $26.5 million for 2025 and $9.7 million for Q3 2026, with royalty revenues of $570,000 in 2025. It maintains a strong liquidity position with $268.9 million in cash and equivalents as of September 30, 2026, and a current ratio above 42. The company has reduced R&D expenses in 2025 due to winding down clinical trials and operates fully remotely since late 2025. Risk factors remain consistent with prior disclosures.

Scenarios for VYNE

Bull case model:

The company’s strong liquidity and reduced operating expenses provide a runway for continued development or strategic initiatives. The wind down of certain clinical trials may allow reallocation of resources to other programs. The fully remote operating model may reduce overhead costs. The company’s royalty revenues, while limited, provide some recurring income. Equity issuances have increased capital availability for operations and development.

Bear case model:

VYNE Therapeutics continues to report net losses with limited revenue generation, reflecting the risks inherent in clinical-stage biopharmaceutical development. The wind down of clinical trials may indicate challenges in advancing pipeline candidates. The company’s accumulated deficit is substantial, and future funding needs may arise. The absence of recent material news specific to VYNE may reflect limited near-term catalysts. Risks related to clinical development, regulatory approval, and market acceptance remain significant.

Moat:

VYNE Therapeutics operates in the biopharmaceutical sector, where competitive advantage typically derives from proprietary drug candidates, clinical trial progress, and intellectual property. The company’s moat is linked to its clinical-stage assets and potential future approvals, though current disclosures indicate a wind down of certain clinical programs. The company’s strong cash position supports ongoing operations and potential development activities. However, as a clinical-stage entity with no significant revenues beyond royalties, its moat depends heavily on successful drug development and regulatory milestones.

Risks overview
Risks summary
The primary risks for VYNE Therapeutics relate to clinical development uncertainties, financial sustainability amid ongoing losses, and regulatory challenges inherent in the biopharmaceutical industry.
Risks details:

• Clinical Development Risk: The company’s future depends on successful development and approval of drug candidates. The wind down of clinical trials for repibresib and VYN202 may impact pipeline prospects.
• Financial Risk: Despite a strong cash position, ongoing net losses and accumulated deficits pose risks to long-term financial sustainability and may require additional capital raises.
• Operational Risk: Transition to a fully remote operating model and reduction in R&D expenses may affect operational capabilities and future development timelines.
• Regulatory Risk: The company faces regulatory uncertainties typical of biopharmaceutical development, including approval processes and compliance requirements.

FINAL FORECAST FOR VYNE

Final take one line
VYNE Therapeutics exhibits very high visibility through detailed SEC disclosures highlighting its clinical-stage biopharmaceutical operations, strong liquidity, and ongoing financial challenges.
Final take 12 to 24 month view

Business trends: The company is managing a transition with reduced R&D expenses following the wind down of certain clinical trials and maintains strong liquidity supported by marketable securities.
Execution milestones: Continued management of clinical development programs, maintaining financial discipline, and operating remotely with no lease obligations.
Key risks: Clinical development uncertainties, sustained net losses requiring capital management, and regulatory approval challenges inherent in the biopharmaceutical sector.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • VYNE Therapeutics Inc. is a publicly reporting company with detailed SEC filings including a 10-K filed on 2026-02-27 and a 10-Q filed on 2026-11-13 [S1][S2].
  • As of September 30, 2026, VYNE had cash and cash equivalents of $268.86 million and total current assets of $273.96 million, with current liabilities of $6.51 million, resulting in a very strong current ratio of 42.08 and a cash ratio of 41.29 [S2].
  • The company reported a net loss of $9.72 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.43 [S2].
  • For the year ended December 31, 2025, VYNE reported total revenues of $570,000 primarily from royalty revenues, operating expenses of $30.3 million, and a net loss of $26.5 million [S1].
  • The company’s accumulated deficit was $757.65 million as of December 31, 2025, with shareholders' equity of $27.77 million [S1].
  • VYNE has significantly increased its shares outstanding from approximately 14.8 million at the end of 2024 to 33.3 million at the end of 2025, reflecting equity issuances [S1].
  • The company operates with a fully remote model since November 1, 2025, and has no operating lease obligations as of December 31, 2025 [S1].
  • VYNE’s research and development expenses decreased from $30.9 million in 2024 to $19.2 million in 2025, reflecting the wind down of clinical trials for repibresib and VYN202 [S1].
  • The company’s sources of funding in 2025 primarily consisted of proceeds from the sale and maturity of marketable securities totaling $68.3 million [S1].
  • VYNE’s risk factors are disclosed in its SEC filings, with no material changes reported as of the latest 10-Q filing [S2].
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-02-27 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | Solesence, Inc. Reports Record Third Quarter 2026 Financial Results | https://www.nasdaq.com/articles/solesence-inc-reports-record-third-quarter-2026-financial-results
  • N2 | 2026-11-13 | www.nasdaq.com | Zimmer Biomet Holdings, Inc. Completes Offerings of €500.0 million 4.375% notes due 2033 and $500.0 million 5.850% notes due 2036 | https://www.nasdaq.com/articles/zimmer-biomet-holdings-inc-completes-offerings-eu5000-million-4375-notes-due-2033-and-5000
  • N3 | 2026-11-13 | www.nasdaq.com | MDxHealth SA Reports Third Quarter 2026 Financial Results and Commercial Restructuring | https://www.nasdaq.com/articles/mdxhealth-sa-reports-third-quarter-2026-financial-results-and-commercial-restructuring
  • N4 | 2026-11-13 | www.nasdaq.com | $1,000 in Main Street Capital's 2007 IPO Is Worth About $7,300 Counting Dividends. It Has Never Cut Its Monthly Payout. | https://www.nasdaq.com/articles/1000-main-street-capitals-2007-ipo-worth-about-7300-counting-dividends-it-has-never-cut
  • N5 | 2026-11-13 | www.nasdaq.com | HireQuest, Inc. Reports $8.8 million Total Revenue for Third Quarter 2026 | https://www.nasdaq.com/articles/hirequest-inc-reports-88-million-total-revenue-third-quarter-2026
  • N6 | 2026-11-13 | www.nasdaq.com | MediWound Q3 Loss Widens On Lower Warrant Gains; EscharEx Enrollment Completion Due In Q1 2027 | https://www.nasdaq.com/articles/mediwound-q3-loss-widens-lower-warrant-gains-escharex-enrollment-completion-due-q1-2027
  • N7 | 2026-08-26 | www.nasdaq.com | Soybeans Extend Gains to Tuesday’s Close | https://www.nasdaq.com/articles/soybeans-extend-gains-tuesdays-close
  • N8 | 2026-08-26 | www.nasdaq.com | ExxonMobil Has Raised Its Dividend 43 Years in a Row. But the Raises Used to Be Bigger. | https://www.nasdaq.com/articles/exxonmobil-has-raised-its-dividend-43-years-row-raises-used-be-bigger
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine